![Senior Manager, Quality Assurance Operations Job in South San Francisco, CA - Puma Biotechnology, Inc | pumabiotechnology.jobs.net Senior Manager, Quality Assurance Operations Job in South San Francisco, CA - Puma Biotechnology, Inc | pumabiotechnology.jobs.net](https://secure.icbdr.com/MediaManagement/GS/I2P6NR63V7ZFCCN7VGS.jpg)
Senior Manager, Quality Assurance Operations Job in South San Francisco, CA - Puma Biotechnology, Inc | pumabiotechnology.jobs.net
![Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1554213706/Pumalounging.jpg/Pumalounging.jpg?VersionId=AXzRJpBb66kBzE1ipO.16_8WJAXmXjo2)
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Final findings from the CONTROL trial of diarrheal prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and
![FDA Approves Dose Escalation Label Update for Puma Biotechnology's NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer | Business Wire FDA Approves Dose Escalation Label Update for Puma Biotechnology's NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer | Business Wire](https://mms.businesswire.com/media/20210701005217/en/889083/23/4357884cpuma_logo_JPEG.jpg)
FDA Approves Dose Escalation Label Update for Puma Biotechnology's NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer | Business Wire
![FDA Approves Dose Escalation Label Update for Puma Biotechnology's NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer | Business Wire FDA Approves Dose Escalation Label Update for Puma Biotechnology's NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer | Business Wire](https://mms.businesswire.com/media/20210701005217/en/889083/22/4357884cpuma_logo_JPEG.jpg)